Abstract
Histoacrylate, scientifically known as n-butyl-2-cyanoacrylate (NBCA), is a form of cyanoacrylate preparation with a long-standing history of utilization in embolization procedures. In March 2022, the NBCA was approved by the pharmaceutical affairs bodies, and in September of the same year was covered by insurance. This is particularly pertinent in cases of polytrauma where numerous points of hemorrhage often exist and the rate of exsanguination surpasses that in other types of hemorrhagic lesions. Due to its reactivity with anions and subsequent polymerization, NBCA is a significantly efficacious embolization agent in trauma IVR, facilitating hemostasis despite potential disruptions in the patient’s coagulation ability. In this article, we recapitulate essential details on trauma care and delineate the clinical implications of employing NBCA in trauma-induced intravascular resuscitation.
